SELF-AMPLIFIED RNA EXPRESSING THE ANTIGENS gB, gBdel, gD, gI, gE and gC OF THE INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILT)

Abstract

The present invention relates to self-amplifying RNA (saRNA) vaccines against infectious laryngotracheitis (ITL) that provide safe and effective prophylactic and therapeutic immune responses and improve the symptoms of the disease. In particular, the invention relates to sRNAs encoding at least one laryngotracheitis virus polypeptide, an ILTV polypeptide variant, or an immunogenic fragment or epitope thereof, said sRNA comprising a first nucleic acid sequence comprising nsP1, nsP2, nsP3 and nsP4 which encode non-structural alphavirus proteins, a second nucleic acid sequence encoding at least one ILTV polypeptide comprising gB or gBdel, gD, gI and / or gE and gC, and also comprising a 5' cap, a 5' UTR upstream of the first nucleic acid sequence, a 26S promoter upstream of the second nucleic acid sequence, a 3' UTR and a poly A tail.The sRNA according to the present invention allows, when incorporated into a cell, the expression of at least one ILTV polypeptide, an ILTV polypeptide variant, or an immunogenic fragment or an epitope of one of them.